The company focused on developing a novel, reversible, all-endoscopic surgical set of tools, which would serve as a safe and simple alternative to surgical treatment for obesity. Their trans-oral solution would avoid complications and safety issues related to conventional incision-based surgery for obesity. The company’s assets were sold in 2013.